CK1α upregulates the IFNAR1 expression to prompt the anti-HBV effect of type I IFN in hepatoma carcinoma cells

Virol Sin. 2022 Dec;37(6):894-903. doi: 10.1016/j.virs.2022.08.004. Epub 2022 Aug 17.

Abstract

Casein kinase 1α (CK1α) mediates the phosphorylation and degradation of interferon-α/β receptor 1 (IFNAR1) in response to viral infection. However, how CK1α regulates hepatitis B virus (HBV) replication and the anti-HBV effects of IFN-α are less reported. Here we show that CK1α can interact with IFNAR1 in hepatoma carcinoma cells and increased the abundance of IFNAR1 by reducing the ubiquitination levels in the presence of HBV. Furthermore, CK1α promotes the IFN-α triggered JAK-STAT signaling pathway and consequently enhances the antiviral effects of IFN-α against HBV replication. Our results collectively provide evidence that CK1α positively regulates the anti-HBV activity of IFN-α in hepatoma carcinoma cells, which would be a promising therapeutic target to improve the effectiveness of IFN-α therapy to cure CHB.

Keywords: Casein kinase 1α (CK1α); Hepatitis B virus (HBV); Interferon-α (IFN-α); Interferon-α/β receptor 1 (IFNAR1).

MeSH terms

  • Carcinoma, Hepatocellular*
  • Casein Kinase Ialpha*
  • Cell Line
  • Hepatitis B virus / physiology
  • Humans
  • Interferon Type I* / metabolism
  • Interferon-alpha / pharmacology
  • Liver Neoplasms*
  • Receptor, Interferon alpha-beta

Substances

  • Casein Kinase Ialpha
  • Interferon Type I
  • Interferon-alpha
  • IFNAR1 protein, human
  • Receptor, Interferon alpha-beta